Connect Biopharma Holdings Limited

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company dedicated to developing innovative therapies for inflammatory diseases, primarily focusing on T cell-driven research. The company's mission is to improve the lives of patients suffering from chronic inflammatory conditions. Headquartered in San Diego, California, Connect Biopharma maintains operations in both the U.S. and China.

The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha (IL-4Rα). This therapy is currently in development for the treatment of atopic dermatitis, asthma, and chronic obstructive pulmonary disease (COPD). Connect Biopharma is also advancing icanbelimod, a modulator of S1P1 T cell receptors, for the treatment of ulcerative colitis.

Recent notable developments include positive topline data from a Phase 1 study of intravenous rademikibart in asthma and COPD patients, announced in March 2026. The company continues enrollment in its Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD, with topline data anticipated in mid-2026. Barry Quart, Pharm.D., serves as the Chief Executive Officer, appointed in June 2024, with David Szekeres as President and Kleanthis G. Xanthopoulos, Ph.D., as Chair of the Board. In March 2026, Connect Biopharma secured $20.2 million in private placement financing, which is expected to extend its cash runway into the second half of 2027.